GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » 3-Year Revenue Growth Rate

Gene Biotherapeutics (Gene Biotherapeutics) 3-Year Revenue Growth Rate : 0.00% (As of Dec. 2020)


View and export this data going back to . Start your Free Trial

What is Gene Biotherapeutics 3-Year Revenue Growth Rate?

Gene Biotherapeutics's Revenue per Share for the three months ended in Dec. 2020 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Competitive Comparison of Gene Biotherapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Gene Biotherapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gene Biotherapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gene Biotherapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Gene Biotherapeutics's 3-Year Revenue Growth Rate falls into.



Gene Biotherapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Gene Biotherapeutics  (OTCPK:CRXM) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Gene Biotherapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Gene Biotherapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Gene Biotherapeutics (Gene Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11230 Sorrento Valley Road, Suite 220, San Diego, CA, USA, 92121
Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
Executives
Andrew M Leitch director 6615 CALLE PONTE BELLA, RANCHO SANTA FE CA 92091
Murray H Hutchison director C/O CADIZ INC., 550 SOUTH HOPE STREET, 2850, LOS ANGELES CA 90071
Dennis Mulroy officer: Chief Financial Officer
Ronald I Simon other: Former Director 485 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Robert N Weingarten director, officer: PRESIDENT and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Gene Biotherapeutics (Gene Biotherapeutics) Headlines